These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30585679)

  • 1. Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire.
    Stocchi F; Coletti C; Bonassi S; Radicati FG; Vacca L
    Eur J Neurol; 2019 May; 26(5):821-826. PubMed ID: 30585679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locomotor response to levodopa in fluctuating Parkinson's disease.
    Moore ST; MacDougall HG; Gracies JM; Ondo WG
    Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
    Hauser RA; Isaacson SH; Ellenbogen A; Safirstein BE; Truong DD; Komjathy SF; Kegler-Ebo DM; Zhao P; Oh C
    Parkinsonism Relat Disord; 2019 Jul; 64():175-180. PubMed ID: 30992235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire.
    Pistacchi M; Gioulis M; Sanson F; Marsala SZ
    Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
    Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
    Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
    Pahwa R; Busenbark K; Huber SJ; Michalek D; Hubble JP; Koller WC
    Neurology; 1993 Apr; 43(4):677-81. PubMed ID: 8469321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
    Metman LV; van den Munckhof P; Klaassen AA; Blanchet P; Mouradian MM; Chase TN
    Neurology; 1997 Sep; 49(3):711-3. PubMed ID: 9305328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease.
    Mostile G; Nicoletti A; Dibilio V; Luca A; Raciti L; Sciacca G; Cicero CE; Vasta R; Donzuso G; Contrafatto D; Zappia M
    Clin Neuropharmacol; 2017; 40(1):6-10. PubMed ID: 27879548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations.
    Merims D; Djaldetti R; Melamed E
    Clin Neuropharmacol; 2003; 26(4):196-8. PubMed ID: 12897640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
    Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
    J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.